PIK-inhibitors are primarily used in the field of cancer therapy. They target specific enzymes involved in the PI3K/AKT/mTOR pathway, which is crucial for cell growth, survival, and metabolism. By inhibiting these enzymes, PIK-inhibitors can effectively slow down or stop the proliferation of cancer cells. They are particularly useful in treating cancers where this pathway is overactive, such as breast, ovarian, and blood cancers. Additionally, PIK-inhibitors are being researched for their potential in treating inflammatory diseases and autoimmune disorders, where abnormal cell signaling contributes to disease progression. Their ability to modulate immune responses makes them a promising option for developing new therapeutic strategies.